Background
Pallavi Prasad
Is all kidney disease in Diabetics "Diabetic ...

In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.

Is all kidney disease in Diabetics "Diabetic Nephropathy"?
Cristina Adriana Popa
NephJC Internship 2026-2027

Introducing NephJC’s brand new editorial internship class of 2026-2027

NephJC Internship 2026-2027
Background
Cristina Adriana Popa
Making an IMPACT on BP: Why pills alone won't ...

This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.

Making an IMPACT on BP: Why pills alone won't win the war
Background
Cristina Adriana Popa
Is TRPC6 inhibition for FSGS a trick or a treat?

This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.

Is TRPC6 inhibition for FSGS a trick or a treat?
Background
Cristina Adriana Popa
Why-dralazine?! Population risk of drug induced ...

This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?

Why-dralazine?! Population risk of drug induced vasculitis

HTN

IMPACTS-BP: The Visual Abstract

Can multifaceted strategies improve hypertension control in low-income patients?

Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood pressure control continues to be a major challenge, especially in low-income populations. The IMPACTS-BP trial has arrived, a study evaluating whether a multifaceted team-based strategy can improve blood pressure control and adherence to antihypertensive therapy.

Check out the VA by Dra Akshaya Jayachandran, and don’t forget to join the live discussion with @NephJC on X and Bluesky

El ensayo IMPACT-BP: El Resumen Visual

¿Puede el trabajo colaborativo mejorar el control de la hipertensión?

La hipertensión arterial continúa siendo uno de los principales factores de riesgo cardiovascular a nivel mundial. Sin embargo, lograr un adecuado control de la presión arterial sigue siendo un desafío, especialmente en poblaciones de bajos ingresos. Hoy aterriza el ensayo IMPACTS-BP, un estudio que evaluó si una estrategia multifacética basada en equipos puede mejorar el control y la adherencia al tratamiento antihipertensivo.

Revisa el resumen visual realizado por la Dra Akshaya Jayachandran y no olvides unirte en vivo con @NephJC en X y Bluesky

Guías AHA/ACC 2025 en Hipertensión: el resumen visual

La hipertensión arterial sigue siendo uno de los principales factores de riesgo modificables para enfermedad cardiovascular y enfermedad renal crónica. Las nuevas guías AHA/ACC 2025 han actualizado aspectos fundamentales sobre la prevención, la evaluación y el tratamiento de la hipertensión, con implicaciones directas para la práctica nefrológica.

Revisa el resumen visual creado por Dr Sejal Lakhani

visual abstract, Visual Abstract, sejal lakhani, Hypertension, HTN, ACC/AHA, 2025